Quantcast

Merck: A Slow And Steady Big Pharma Dividend Grower, But Better Alternatives Exist

Posted On November 13, 2017 8:32 am
By:

Merck has long been known as a boring, and safe dividend investment. While that may be true, the company’s numerous challenges and slow growth rate mean there are better drug makers to buy today.

Continue Reading Here

About author

Dividend Sensei
Dividend Sensei

I'm an Army veteran and former energy dividend writer for The Motley Fool. I'm a proud co-founder of Wide Moat Research, Dividend Kings, and the Intelligent Dividend Investor. My work can be found on Seeking Alpha, Dividend Kings, iREIT, and the Intelligent Dividend Investor. My goal is to help all people learn how to harness the awesome power of dividend growth investing to achieve their financial dreams and enrich their lives. With 24 years of investing experience, I've learned what works and more importantly, what doesn't, when it comes to building long-term wealth and income streams and achieving long-term financial goals.

Related Articles

Leave a reply

Your email address will not be published. Required fields are marked *